DYAI vs. NLTX, CYBN, SLRN, MDWD, IVVD, PLX, HURA, PLRX, NBTX, and INBX
Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Neoleukin Therapeutics (NLTX), Cybin (CYBN), Acelyrin (SLRN), MediWound (MDWD), Invivyd (IVVD), Protalix BioTherapeutics (PLX), TuHURA Biosciences (HURA), Pliant Therapeutics (PLRX), Nanobiotix (NBTX), and Inhibrx (INBX). These companies are all part of the "pharmaceutical products" industry.
Dyadic International vs.
Dyadic International (NASDAQ:DYAI) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Dyadic International received 111 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 64.40% of users gave Dyadic International an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Dyadic International presently has a consensus price target of $6.00, indicating a potential upside of 305.41%. Given Dyadic International's stronger consensus rating and higher possible upside, equities analysts clearly believe Dyadic International is more favorable than Neoleukin Therapeutics.
In the previous week, Neoleukin Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 2 mentions for Neoleukin Therapeutics and 0 mentions for Dyadic International. Neoleukin Therapeutics' average media sentiment score of 0.92 beat Dyadic International's score of 0.00 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media.
Neoleukin Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -188.09%. Neoleukin Therapeutics' return on equity of -37.22% beat Dyadic International's return on equity.
Dyadic International has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
28.0% of Dyadic International shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 28.8% of Dyadic International shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Dyadic International has higher revenue and earnings than Neoleukin Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Dyadic International beats Neoleukin Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Dyadic International News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyadic International Competitors List
Related Companies and Tools
This page (NASDAQ:DYAI) was last updated on 2/22/2025 by MarketBeat.com Staff
